Minerva Neurosciences, Inc
NERV Real Time Price USDRecent trades of NERV by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by NERV's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
NERV Revenue by Segment or Geography
No Revenue by Segment data for this ticker
No Revenue by Geography data for this ticker
New patents grants
-
Patent Title: Gastro-resistant controlled release oral dosage forms Jul. 30, 2024
-
Patent Title: Sigma ligand compounds and uses thereof Jun. 11, 2024
-
Patent Title: Methods of using a phenoxypropylamine compound to treat pain Sep. 26, 2023
-
Patent Title: Gastro-resistant controlled release oral dosage forms Oct. 11, 2022
-
Patent Title: Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection Aug. 10, 2021
-
Patent Title: Compositions and methods for treating schizophrenia Oct. 13, 2020
-
Patent Title: Compositions and methods for treating schizophrenia Apr. 16, 2019
-
Patent Title: Methods of use of cyclic amide derivatives to treat schizophrenia Aug. 15, 2017
-
Patent Title: Compositions and methods for treating schizophrenia Aug. 15, 2017
-
Patent Title: Compositions and methods for treating schizophrenia Oct. 04, 2016
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to NERV
Number of mentions of NERV in WallStreetBets Daily Discussion
Recent picks made for NERV stock on CNBC
ETFs with the largest estimated holdings in NERV
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view NERV Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.